Hemogenyx Pharmaceuticals plc (LSE: HEMO) announced on Monday that it has recruited a second patient for its clinical trial of HG-CT-1, a proprietary CAR-T cell therapy for relapsed or refractory acute myeloid leukemia (R/R AML) in adults.

This milestone marks continued progress in developing a potentially life-saving treatment for patients with limited options.

Manufacturing of HG-CT-1 for the second patient will commence shortly, led by the company's scientific and quality control teams. Further updates on the trial will follow in due course.

Headquartered in London, Hemogenyx Pharmaceuticals operates through its US subsidiaries in New York, focusing on innovative therapies for blood and autoimmune diseases. The company is advancing multiple product candidates and platform technologies to drive novel treatment development.